Thalys Medical Technology Group 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Zheng Wang

최고 경영자

CN¥1.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.0009%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

Thalys Medical Technology Group Corporation (SHSE:603716) Shares Fly 26% But Investors Aren't Buying For Growth

Nov 20

Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Aug 12

CEO

Zheng Wang (57 yo)

no data

테뉴어

CN¥1,005,300

보상

Mr. Zheng Wang serves as Director at Thalys Medical Technology Group Inc. and serves as its General Manager. He served as Deputy General Manager at Thalys Medical Technology Group Inc. (formerly known as T...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zheng Wang	GM & Director	no data	CN¥1.01m	0.00086% CN¥ 14.5k
Yan Shen	Chief Financial Officer	1.8yrs	CN¥400.90k	데이터 없음
Li Fan	Deputy GM	no data	CN¥600.00k	0.0080% CN¥ 135.4k
Xiao Ming Wen	Director of GM Office & Director	no data	CN¥644.00k	데이터 없음
Feng Cai	Board Secretary	2.2yrs	CN¥600.00k	0.0053% CN¥ 90.3k
Yi Lu	Deputy General Manager	1.9yrs	CN¥698.00k	0.012% CN¥ 203.1k
Jun Sun	Administrative Director	no data	데이터 없음	데이터 없음
Feng Liu	GM of SPD Business & Regional Inspection Center Business Department and Deputy GM	no data	CN¥704.00k	데이터 없음

1.9yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 603716 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zheng Wang	GM & Director	no data	CN¥1.01m	0.00086% CN¥ 14.5k
Li Fan	Deputy GM	no data	CN¥600.00k	0.0080% CN¥ 135.4k
Xiao Ming Wen	Director of GM Office & Director	no data	CN¥644.00k	데이터 없음
Zhaoguo Zhang	Independent Director	less than a year	데이터 없음	데이터 없음
Wei Wen	Chairman	no data	CN¥900.00k	5.15% CN¥ 87.0m
Yicheng Wen	Director	no data	CN¥425.30k	데이터 없음
De Chen	Assistant to the GM & Chairman of the Supervisory Board	no data	데이터 없음	데이터 없음
Jing Tu	Supervisor	no data	데이터 없음	데이터 없음
Fei Xiong	Director of Bidding	no data	데이터 없음	데이터 없음
Zhen Zhang	Independent Director	less than a year	데이터 없음	데이터 없음
Xianwang Shi	Independent Director	less than a year	데이터 없음	데이터 없음

0.3yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 이사회: 603716 의 이사회는 경험(평균 재직 기간 0.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Thalys Medical Technology Group 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024

Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Thalys Medical Technology Group Corporation (SHSE:603716) Shares Fly 26% But Investors Aren't Buying For Growth

Third quarter 2024 earnings released: CN¥0.42 loss per share (vs CN¥0.033 loss in 3Q 2023)

Wuhan Herun Ruihui Business Consulting Co., Ltd. agreed to acquire 80% stake in Wuhan Huixin Technology Development Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 72 million.

Thalys Medical Technology Group Corporation to Report Q3, 2024 Results on Oct 29, 2024

Thalys Medical Technology Group Corporation (SHSE:603716) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Thalys Medical Technology Group Corporation to Report First Half, 2024 Results on Aug 30, 2024

Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares.

Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.07 loss in 1Q 2023)

Thalys Medical Technology Group Corporation, Annual General Meeting, May 20, 2024

Thalys Medical Technology Group Corporation to Report Q1, 2024 Results on Apr 27, 2024

An undisclosed buyer acquired 51% stake in Shanxi Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation (SHSE:603716) for CNY 1.53 million.

Thalys Medical Technology Group Corporation (SHSE:603716) announces an Equity Buyback for CNY 20 million worth of its shares.

Thalys Medical Technology Group Corporation to Report Fiscal Year 2023 Results on Apr 27, 2024

New major risk - Financial position

Second quarter 2023 earnings released: EPS: CN¥0.084 (vs CN¥0.099 loss in 2Q 2022)

New minor risk - Share price stability

Thalys Medical Technology Group Corporation to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.016 loss per share (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.099 loss per share (vs CN¥0.012 loss in 2Q 2021)

Huang Jianfeng completed the acquisition of Thalys Medical Technology Group Inc. (SHSE:603716) from Saihai (Shanghai) Health Technology Co., Ltd.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Second quarter 2021 earnings released: CN¥0.012 loss per share (vs CN¥0.18 profit in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.12 loss in 1Q 2020)

New 90-day low: CN¥14.45

New 90-day low: CN¥14.50

New 90-day high: CN¥17.71

New 90-day low: CN¥14.70

Third quarter earnings released

Thalys Medical Technology Group Inc. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high - CN¥18.10

First half earnings released

Thalys Medical Technology Inc. (SHSE:603716) agreed to acquire remaining 49% stake in Shanghai Thalys Medical Technology Co., Ltd. from Liu Hongkui and Zhang Luqi for CNY 0.

New 90-day high - CN¥17.33

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령